Therapeutic Opportunities in Melanoma Through PRAME Expression

Area of Science:

• Oncology
• Immunology
• Dermatopathology

Background:

• Melanoma diagnosis is challenging due to similarities with benign lesions.
• Immunohistochemistry (IHC) aids diagnosis in difficult cases.
• Preferentially Expressed Antigen in Melanoma (PRAME) is a key marker.

Purpose of the Study:

• To review PRAME's role in melanoma diagnosis, prognosis, and therapy.
• To evaluate PRAME's diagnostic utility versus benign nevi.
• To explore PRAME's therapeutic potential in immunotherapy.

Main Methods:

• Literature review of PRAME expression in melanocytic lesions and malignancies.
• Analysis of PRAME's integration into IHC protocols.
• Evaluation of PRAME-directed investigational therapies.

Main Results:

• PRAME shows high specificity and sensitivity in differentiating melanoma subtypes.
• PRAME overexpression correlates with poor prognosis in malignancies.
• PRAME-directed therapies show promise but face challenges like immune evasion.

Conclusions:

• PRAME is a valuable biomarker for melanoma diagnosis and a target for immunotherapy.
• PRAME supports clinical utility in diagnostic precision, prognostic assessment, and precision oncology.
• Overcoming immune evasion is crucial for optimizing PRAME-directed therapies.